http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0863993-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_916075766043ce900399a4c2eee9f054 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-32 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-18 |
| filingDate | 1996-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30474c29c66896d5d679f697151cb34e |
| publicationDate | 1998-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0863993-A1 |
| titleOfInvention | Method of screening anti-amebic agents |
| abstract | There is disclosed an assay method of screening and identification of anti-amebic drugs which utilizes the ability to inhibit anaerobic growth of a novel bacterial mutant that expresses the EhADH2 gene and which bypasses the conventional need for a parasitic culture. The novel mutant, designated E. coli/EhADH2, is cultured under anaerobic conditions, a predetermined or known quantity of the agent to be tested or target compound is combined with the cell culture, and the combination is then monitored to determine the inhibitory effect upon the anaerobic growth of the E. coli/EhADH2 cell mutant. |
| priorityDate | 1995-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 274.